Emerging biopharmaceutical company selects clinivation’s Regulatory solution to support the development of its global regulatory strategy.
Natick, MA, January 22, 2008 – clinivation, Inc. announced today that Indigene Pharmaceuticals, Inc. has selected clinivation’s Regulatory solution.
“Indigene Pharma is clearly an emerging leader in the development of molecular entities for prescription and consumer healthcare products,” said Joseph Kozikowski, M.D., clinivation’s President and Chief Executive Officer. “We are pleased that Indigene’s senior management has selected clinivation to help position their products for continued growth and expansion,” he continued.
Clinivation’s Regulatory Practice delivers expertise, experience, and an outstanding track record.
About Indigene Pharmaceuticals, Inc.
Indigene, a rapidly growing biopharmaceutical company, was founded in 2002 with a strategic focus to rapidly develop and deliver innovative, safe, and effective molecular combination based healthcare products. We call this unique offering Multiceutics™. These molecular combinations are optimized to work simultaneously on multiple pathways associated with diseases and symptoms of the human body. This unique product development approach results in smarter medicines, as compared to the traditional Pharma industry approach of using a single molecule to target a single pathway among the network of multiple pathways that are associated with diseases and symptoms.
For further information, please visit www.indigenepharma.com.